A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 5, Issue 5, 2005, Pages 519-529

  Bansback, Nick ^a,b   Brennan, Alan ^a   Anis, Aslam H ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Adalimumab; Biologic response; Modifier; Quality of life; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EMPLOYMENT; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; JOINT DESTRUCTION; JOINT FUNCTION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PREVALENCE; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

EID: 27744483582     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.5.5.519     Document Type: Review

References (59)

1. Lee DM, Weinblatt ME: Rheumatoid arthritis. Lancet 358, 903-911 (2001).
2. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 27, 269-281 (2001).
3. Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM. Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann. Rheum. Dis. 61, 818-821 (2002).
4. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 46, 328-346 (2002).
5. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N. Engl. J. Med. 350, 2167-2179 (2004).
6. O'Dell JR. Drug therapy: therapeutic strategies for rheumatoid arthritis. N. Engl J. Med. 350, 2591-2602 (2004).
7. Bansback N, Regier DA, Ara R et al. A critical review of cost-effectiveness analyses of TNF-α antagonists in rheumatoid arthritis. Drugs 65(4), 473-449 (2005).
8. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patient taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum. 48(1), 35-45 (2003).
9. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo-controlled, 52 week trial, Arthritis Rheum. 50(5), 1400-1411 (2004).
10. van de Putte LBA, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63, 508-516 (2004).
11. Furst DE, Schiff MH, Fleischmann RM et al. Adalimumab, a fully human anti tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid arthritis), J. Rheumatol. 30, 2563-2571 (2003).
12. Breedveld FC, Weisman MH, Kavanaugh AF et al. The efficacy and safety of adalimumab (HUMIRA®) plus methotrexate vs. adalimumab alone or methotrexate alone in the early treatment of rheumatoid arthritis: 1- and 2- year results of the PREMIER study. Ann. Rheum. Dis. 64(3), 60 (2005).
13. Weinblatt M, Kremer J, Bankhurst A et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fiision protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253-259 (1999).
14. Moreland L, Schiff M, Baumgartner S et al. Etanercept therapy in rheumatoid arthritis: a randomised, controlled trial. Ann. Intern. Med. 130, 478-486 (1999).
15. Bathon J, Martin R, Fleischmann R et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586-1593 (2000).
16. Klareskog L, van der Heijde D, de Pager JP et al. Therapeutic effct of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675-681 (2004).
17. Maini R, St Clair E, Breedveld F et al. Infliximab (chimeric antitumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. Lancet 359, 1932-1939 (1999).
18. St.Clair WE, Desiree MF, van der Heijde M et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum. 50(11), 3432-3443 (2004).
19. Breshinan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid artritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41(12) 2196-2204. (1998).
20. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum. 46, 614-624 (2002).
21. Cohen SB, Moreland LW, Cush JJ et al. A multicentre, double-blind, randomised, placebo-controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63(9), 1062-1068 (2004).
22. Tesser J, Fleischmann R, Dore R et al. Concomitant medication use in a large, international, multicenter, placebo-controlled trial of anakinra, a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis. J. Rheumatol. 31(4), 649-654 (2004).
23. Burls A, Jobanputra P. The trials of anakinra. Lancet 4364(9437), 827-828 (2004).
24. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 62(Suppl. 2ii) 13-16 (2003).
25. Clark W, Jobanputra P, Barton P. Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol. Assess. 8(18), iii-iv, ix-x, 1-105 (2004).
26. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 43(1), 22-29 (2000).
27. Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in healthcare. Ann. Rev. Public Health 21, 587-611 (2000).
28. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. In: Methods for the Economic Evaluation of Healthcare Programmes, Second Edition. Oxford University Press, Oxford, UK (1997).
29. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford University Press, NY, USA (1996).
30. Torrance GW, Tugwell P, Amorosi S, Chartash E, Sengupta N. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology 43(6), 712-718 (2004).
31. Feeny DH, Torrance GW, Furlong WJ. Health utilities index. In: Quality of Life and Pharmacoeconomics in Clinical Trials, Second Edition. Spilker B (Ed.), Lippincott-Raven Press, PA, USA 239-252 (1996).
32. Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation Health Technol. Assess. 3(9) 8 (1999).
33. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The Health Assessment Questionnaire, disability and pain scales. J. Rheumatol. 9, 789-793 (1982).
34. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol. Assess. 8 (11iii), 1-91 (2004).
35. Chiou C-F, Choi J, Reyes CM. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis. Expert Rev. Pharmacoeconomics Outcomes Res. 4(3), 307-315 (2004).
36. Haraoui B. Differentiating the efficacy of tumor necrosis factor inhibitors. J. Rheumatol. 74(Suppl.), 3-7 (2005).
37. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 65(5), 661-694 (2005).
38. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 48(10), 2750-2562 (2003).
39. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 42(2), 347-356 (1999).
40. Wong JB. Cost-effectiveness of antitumor necrosis factor agents. Clin. Exp. Rheumatol. 22(5 Suppl. 35), S65-S67 (2004).
41. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J. Rheumatol. 24, 43-48 (1997).
42. Yelin EH, Trupin LS, Katz PP, Lubeck DP, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. 48(11), 3046-3054 (2003).
43. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum. 43, 2316-2327 (2002).
44. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am. J. Med. 113, 400-408 (2002).
45. Kobelt G, Jonsson L, Young A et al. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 42, 326-335 (2003).
46. Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in The Netherlands. Arthritis Rheum. 15, 51(6), 964-973 (2004).
47. Brennan A, Bansback NJ, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43, 62-72 (2004).
48. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of healthcare: selecting the appropriate approach. J. Health Serv. Res. Policy 9(2), 110-118 (2004).
49. Bansback N, Brennan A, Ghatnekar O. The cost effectiveness of adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden. Ann. Rheum. Dis. 64, 995-1002 (2005).
50. Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 19(10), 1051-1064 (2001).
51. Keystone EC. Safety of biologic therapies - an update. J Rheumatol. 32(Suppl. 74), 8-12 (2005).
52. Dixon W, Symmons D, Silman A, Watson K, Hyrich K. Serious infection rates in patients receiving Biologic therapy in the United Kingdom: Results from the BSR Biologics Register (BSRBR). Ann. Rheum. Dis. 64(Suppl. 3), 86 (2005).
53. Askling J, Bertilsson L, Romanus V et al. Risk of tuberculosis in rheumatoid arthritis and following antiTNF treatment. Preliminary results of an ongoing Swedish monitoring programme of biologics in RA. Ann. Rheum. Dis. 64(Suppl. 3), 88 (2005).
54. van Vollenhoven RF. Switching between biological agents. Clinical experimental Rheumatology 22(Suppl. 35) S115-S121 (2004).
55. Newhouse JP. US and UK Health Economics: two disciplines separated by a common language? Health Econ. 7, S79-S92 (1998).
56. Cutler D, Richardson E. The value of health: 1970-1990. American Economic Review Papen and Proceedings 88, 97-100 (1998).
57. Sokka T. Work disability in early rheumatoid arthritis. Clin. Exp. Rheumatol 21(Suppl. 31), S71-S74 (2003).
58. Yelin E, Henke C, Epstein W. Work dynamics of the person with rheumatoid arthritis. Arthritis Rheum. 30, 507-512 (1987).
59. Bain B, Brazil M. Adalimumab. Nature Rev. Drug Discov. 2(9), 693-694 (2003).